Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UCHL1 | P09936 | 11/20 | 0.35 |
| ▸ | UCHL3 | P15374 | 1/20 | 0.35 |
| ▸ | TGM2 | P21980 | 1/20 | 0.35 |
| ▸ | CASP3 | P42574 | 1/20 | 0.35 |
| ▸ | USP5 | P45974 | 1/20 | 0.35 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.33 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.33 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.33 |
| ▸ | BCKDK | O14874 | 1/20 | 0.32 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.32 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.32 |
| ▸ | DAO | P14920 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2947166 | 0.85 | LIMK1 (0.33) | UCHL1UCHL3TGM2CASP3USP5 | |
| SCHEMBL5648879 | 0.78 | KDM4E (0.41) | UCHL1UCHL3TGM2CASP3USP5 | |
| SCHEMBL29163700 | 0.67 | PDE3B (0.39) | PDE3BPDE3A | |
| SCHEMBL22310341 | 0.67 | PIM1 (0.41) | PDE3BPDE3A | |
| SCHEMBL12895320 | 0.65 | GPR35 (0.35) | GPR35BCKDKMCL1RXFP1DAO | |
| SCHEMBL346530 | 0.65 | MCL1 (0.62) | MCL1RXFP1 | |
| SCHEMBL11804199 | 0.64 | GPR35 (0.48) | GPR35MCL1RXFP1DAO | |
| SCHEMBL4277521 | 0.63 | MCL1 (0.67) | GPR35BCKDKMCL1RXFP1 | |
| SCHEMBL3492612 | 0.62 | IKBKB (0.55) | GPR35RXFP1 | |
| SCHEMBL1267416 | 0.62 | ALDH1A1 (0.36) | MCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7763729-B2 | Bicyclic heteroaromatic derivatives | UCB PHARMA S.A. (BE) | 2010-07-27 | — | — | US | disclosed |
| US-20090042877-A1 | Bicyclic Heteroaromatic Derivatives | CELLTECH R&D LIMITED (GB) | 2009-02-12 | — | — | US | disclosed |
| US-7423047-B2 | Arylamine substituted bicyclic heteroaromatic compounds as p38 kinase inhibitors | CELLTECH R&D LIMITED (GB) | 2008-09-09 | — | — | US | disclosed |
| US-20060004025-A1 | Arylamine substututed bicyclic heteroaromatic compounds as p38 kinase inhibitors | UCB PHARMA S.A. (BE) | 2006-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004025-A1 | Arylamine substututed bicyclic heteroaromatic compounds as p38 kinase inhibitors | MAPK1, CNKSR1, ALK | UCHL1 2918/4885UCHL3 2937/4885TGM2 4241/4885 |
| US-20090042877-A1 | Bicyclic Heteroaromatic Derivatives | MAPK1, CNKSR1, CBR1 | UCHL1 2444/4885UCHL3 2660/4885TGM2 4271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.